News coverage about Diffusion Pharmaceuticals (NASDAQ:DFFN) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.3465577601162 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Diffusion Pharmaceuticals (NASDAQ DFFN) traded up $0.52 during midday trading on Tuesday, hitting $1.73. 8,186,180 shares of the company traded hands, compared to its average volume of 1,455,170. The stock has a market capitalization of $18.15, a PE ratio of -0.45 and a beta of -0.78. Diffusion Pharmaceuticals has a one year low of $1.06 and a one year high of $15.50.
ILLEGAL ACTIVITY NOTICE: This news story was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/01/09/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-diffusion-pharmaceuticals-dffn-share-price.html.
Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.